在小鼠脚掌模型中进行药物疗效测试研究。
Drug Efficacy Testing in the Mouse Footpad Model of Buruli Ulcer.
机构信息
Center for TB Research, Johns Hopkins University, Baltimore, MD, USA.
出版信息
Methods Mol Biol. 2022;2387:195-207. doi: 10.1007/978-1-0716-1779-3_19.
Abstract
Great progress has been made in understanding the pathogenesis and treatment of Buruli ulcer over the last 20 years. The rediscovery of the mouse footpad model of the disease with translation to clinical practice has changed treatment of this infectious disease, caused by Mycobacterium ulcerans, from surgery and skin grafting to the administration of antibiotics for 8 weeks or less with superior cure rates. Here we describe the development and enhancement of the mouse model during the last two decades.
摘要
在过去的 20 年中，人们在了解布吕利溃疡的发病机制和治疗方法方面取得了巨大进展。随着该疾病的鼠足垫模型的重新发现及其向临床实践的转化，导致该病的溃疡分枝杆菌的治疗方法已从手术和植皮转变为 8 周或更短时间内使用抗生素治疗，治愈率更高。本文描述了过去二十年中该小鼠模型的发展和改进。
相似文献
1
Drug Efficacy Testing in the Mouse Footpad Model of Buruli Ulcer.
Methods Mol Biol. 2022;2387:195-207. doi: 10.1007/978-1-0716-1779-3_19.
2
Shortening Buruli Ulcer Treatment with Combination Therapy Targeting the Respiratory Chain and Exploiting Mycobacterium ulcerans Gene Decay.
Antimicrob Agents Chemother. 2019 Jun 24;63(7). doi: 10.1128/AAC.00426-19. Print 2019 Jul.
3
Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model.
Antimicrob Agents Chemother. 2012 Feb;56(2):687-96. doi: 10.1128/AAC.05543-11. Epub 2011 Dec 5.
4
In vitro antibacterial activity and in vivo efficacy of hydrated clays on Mycobacterium ulcerans growth.
BMC Complement Altern Med. 2016 Jan 30;16:40. doi: 10.1186/s12906-016-1020-5.
5
Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?
Future Microbiol. 2011 Oct;6(10):1185-98. doi: 10.2217/fmb.11.101.
6
Therapeutic efficacy of rifalazil (KRM-1648) in a M. ulcerans-induced Buruli ulcer mouse model.
PLoS One. 2022 Oct 6;17(10):e0274742. doi: 10.1371/journal.pone.0274742. eCollection 2022.
7
Toward a Single-Dose Cure for Buruli Ulcer.
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.00727-20.
8
Using bioluminescence to monitor treatment response in real time in mice with Mycobacterium ulcerans infection.
Antimicrob Agents Chemother. 2011 Jan;55(1):56-61. doi: 10.1128/AAC.01260-10. Epub 2010 Nov 15.
9
Overview: Development of Drugs Against Mycobacterium ulcerans.
Methods Mol Biol. 2022;2387:185-187. doi: 10.1007/978-1-0716-1779-3_17.
10
Activities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in mice.
PLoS Negl Trop Dis. 2011 Jan 4;5(1):e933. doi: 10.1371/journal.pntd.0000933.
引用本文的文献
1
A composite subunit vaccine confers full protection against Buruli ulcer disease in the mouse footpad model of Mycobacterium ulcerans infection.
PLoS Negl Trop Dis. 2025 Feb 21;19(2):e0012710. doi: 10.1371/journal.pntd.0012710. eCollection 2025 Feb.
本文引用的文献
1
Shortening Buruli Ulcer Treatment with Combination Therapy Targeting the Respiratory Chain and Exploiting Mycobacterium ulcerans Gene Decay.
Antimicrob Agents Chemother. 2019 Jun 24;63(7). doi: 10.1128/AAC.00426-19. Print 2019 Jul.
2
Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer.
PLoS Negl Trop Dis. 2018 Aug 13;12(8):e0006728. doi: 10.1371/journal.pntd.0006728. eCollection 2018 Aug.
3
Preclinical Efficacy Testing of New Drug Candidates.
Microbiol Spectr. 2017 Jun;5(3). doi: 10.1128/microbiolspec.TBTB2-0034-2017.
4
FVB/N Mice Spontaneously Heal Ulcerative Lesions Induced by Mycobacterium ulcerans and Switch M. ulcerans into a Low Mycolactone Producer.
J Immunol. 2016 Mar 15;196(6):2690-8. doi: 10.4049/jimmunol.1502194. Epub 2016 Feb 12.
5
Efficacy of Rifampin Plus Clofazimine in a Murine Model of Mycobacterium ulcerans Disease.
PLoS Negl Trop Dis. 2015 Jun 4;9(6):e0003823. doi: 10.1371/journal.pntd.0003823. eCollection 2015.
6
Accelerated detection of mycolactone production and response to antibiotic treatment in a mouse model of Mycobacterium ulcerans disease.
PLoS Negl Trop Dis. 2014 Jan 2;8(1):e2618. doi: 10.1371/journal.pntd.0002618. eCollection 2014.
7
Rapid, serial, non-invasive assessment of drug efficacy in mice with autoluminescent Mycobacterium ulcerans infection.
PLoS Negl Trop Dis. 2013 Dec 19;7(12):e2598. doi: 10.1371/journal.pntd.0002598. eCollection 2013.
8
Bactericidal activity does not predict sterilizing activity: the case of rifapentine in the murine model of Mycobacterium ulcerans disease.
PLoS Negl Trop Dis. 2013;7(2):e2085. doi: 10.1371/journal.pntd.0002085. Epub 2013 Feb 28.
9
Autoluminescent Mycobacterium tuberculosis for rapid, real-time, non-invasive assessment of drug and vaccine efficacy.
PLoS One. 2012;7(1):e29774. doi: 10.1371/journal.pone.0029774. Epub 2012 Jan 11.
10
Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?
Future Microbiol. 2011 Oct;6(10):1185-98. doi: 10.2217/fmb.11.101.
Zotero 插件